Global Oxygen Delivery Equipment Market Strategic Research Report

Scope of the Report

The global Oxygen Delivery Equipment market size is predicted to grow from US$ 14,869 million in 2025 to US$ 23,298 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.

Oxygen delivery equipment refers to a category of medical devices that transport oxygen from storage or generation systems to the patient's respiratory tract to correct hypoxic symptoms, provide cardiopulmonary support, or deliver therapeutic gases. Its technical essence lies in precisely controlling oxygen concentration, flow rate, and delivery mode to meet diverse oxygen therapy needs ranging from intensive care to home-based rehabilitation. From a product morphology perspective, oxygen delivery equipment encompasses two major tiers: oxygen source devices and patient interface devices. Oxygen source devices include oxygen concentrators, liquid oxygen tanks, and high-pressure oxygen cylinders. Among these, oxygen concentrators utilize molecular sieve pressure swing adsorption technology to separate oxygen from ambient air and represent the mainstream choice for home oxygen therapy, while oxygen cylinders primarily serve emergency transport and high-flow oxygen delivery. Patient interface devices include nasal cannulas, oxygen masks, high-flow nasal cannulas, and high-flow nasal oxygen therapy systems, with their design directly affecting oxygen utilization efficiency and patient comfort. In clinical classification, oxygen delivery equipment can be divided into life support grade and long-term care grade. The former, represented by extracorporeal membrane oxygenation systems and high-flow nasal oxygen therapy systems, is used in intensive care and perioperative management; the latter, represented by home oxygen concentrators and portable oxygen concentrators, serves home-based rehabilitation for patients with chronic respiratory diseases. Currently, with population aging and the rising prevalence of chronic respiratory diseases, the functional positioning of oxygen delivery equipment is extending from clinical treatment tools toward full-cycle health management platforms.

Market Development Opportunities and Key Drivers

In March 2026, Shenzhen Hannuo Medical's single-use membrane oxygenator received FDA clearance in the United States, with its ECMO system having previously obtained domestic and EU certifications, marking the entry of domestically produced extracorporeal life support equipment into the global mainstream market. In the high-altitude oxygen supply sector, Berlin Shenkang's oxygen concentrator, featuring self-developed four-tower rotary valve technology, achieves a service life exceeding 100,000 hours and normal operation in -40°C environments, with an intelligent remote monitoring system enabling real-time transmission of parameters such as oxygen concentration, flow rate, and pressure. In the mobile oxygen therapy sector, in January 2026, Raymed announced an investment of 10 million RMB to establish a joint venture company to expand into high-altitude mobile oxygen therapy, promoting the implementation of an "intelligent mobile oxygen supply combination solution" across home, travel, high-altitude, and emergency scenarios.

Market Challenges and Risks

The raw material for ECMO's most critical component, the membrane oxygenator—PMP polyolefin material—is supplied exclusively by a single company globally, exposing domestically produced equipment to significant supply chain risks. Imported brands have long dominated the market, with German company Maquet holding 60% to 80% of the domestic ECMO market share, making domestic substitution challenging. Hannuo Medical accumulated losses exceeding 670 million RMB from 2022 to the first half of 2025, with net cash flow from operating activities remaining negative and its asset-liability ratio climbing from 31.96% to 72.36%. Although its core products have been adopted in over 140 hospitals nationwide, the million-yuan unit price has not yet generated scaled revenue.

Downstream Demand Trends

In March 2026, the core component of Hannuo Medical's ECMO system—the single-use membrane oxygenator—received FDA clearance, with the domestically produced ECMO system having now obtained market access in over 40 countries and regions globally, laying the regulatory foundation for the overseas expansion of domestically produced high-end oxygen therapy equipment. In the high-altitude oxygen supply sector, Berlin Shenkang secured three consecutive high-altitude oxygen supply project contracts in January 2026, with full-year orders already filled. In the mobile oxygen therapy sector, Raymed's mobile oxygen therapy business, established in January 2026, covers home, travel, high-altitude, and emergency scenarios, building a complete product matrix from stationary oxygen stations to portable devices. The large-scale production of domestically produced ECMO will fundamentally reduce dependence on imported equipment, providing equipment support for national public health security and critical care capacity enhancement.

Regional Trends

North America, leveraging its mature regulatory system and reimbursement mechanisms, continues to lead technology validation and market access for high-end oxygen therapy equipment. In March 2026, Hannuo Medical's membrane oxygenator received FDA clearance, marking the first entry of a domestically produced ECMO core component into the U.S. market and demonstrating the technological maturity of Chinese manufacturing in the high-end life support equipment sector. Europe maintains its advantage in clinical evidence accumulation and standardization, with Hannuo Medical's ECMO system receiving EU-recognized TÜV SÜD certification in 2025, laying the foundation for entry into mainstream European markets. In the Asia-Pacific region, China is emerging as the most dynamic growth area for oxygen therapy equipment. ECMO devices from Jinan, Shenzhen, and other cities have successively received approvals, reflecting the growing regional clustering effect in high-end medical device manufacturing. Domestic brands such as Raymed and Berlin Shenkang are expanding into new sectors including mobile oxygen therapy and high-altitude oxygen supply, with Berlin Shenkang's products already exported to Peru, Uzbekistan, Indonesia, and other countries. In 2025, Jinan's local technology conversion rate maintained double-digit growth for three consecutive years, with technology contract transaction value exceeding 100 billion RMB.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oxygen Delivery Equipment market?

What factors are driving Oxygen Delivery Equipment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oxygen Delivery Equipment market opportunities vary by end market size?

How does Oxygen Delivery Equipment break out by Type, by Application?

This report presents a comprehensive overview of the global Oxygen Delivery Equipment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Oxygen Concentrators
• Oxygen Cylinders
• Nasal Cannulas
• Oxygen Masks

Segment by Technology Principle

• Stored Oxygen
• Membrane Separation
• Cryogenic Air Separation
• Pressure Swing Adsorption
• Chemical Oxygen Generation

Segment by Oxygen Concentration

• Low Concentration
• Medium Concentration
• High Concentration

Segment by Mobility

• Stationary Devices
• Portable Devices

Segment by Application

• Respiratory Disease
• Emergency Medicine
• High Altitude Medicine
• Sports Medicine

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Oxygen Delivery Equipment market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Respiratory Disease, Emergency Medicine, High Altitude Medicine evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact